Protara Therapeutics (TARA) Equity Average (2016 - 2026)
Protara Therapeutics' Equity Average history spans 13 years, with the latest figure at $188.8 million for Q1 2026.
- Quarterly Equity Average rose 15.97% to $188.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $188.8 million through Mar 2026, up 15.97% year-over-year, with the annual reading at $181.8 million for FY2025, 54.4% up from the prior year.
- Equity Average came in at $188.8 million for Q1 2026, up from $164.4 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $188.8 million in Q1 2026 to a low of $63.4 million in Q1 2024.
- The 5-year median for Equity Average is $124.5 million (2024), against an average of $121.6 million.
- Year-over-year, Equity Average plummeted 43.02% in 2023 and then skyrocketed 156.94% in 2025.
- Protara Therapeutics' Equity Average stood at $120.6 million in 2022, then plummeted by 39.78% to $72.6 million in 2023, then skyrocketed by 71.35% to $124.5 million in 2024, then surged by 32.05% to $164.4 million in 2025, then increased by 14.88% to $188.8 million in 2026.
- Per Business Quant, the three most recent readings for TARA's Equity Average are $188.8 million (Q1 2026), $164.4 million (Q4 2025), and $138.4 million (Q3 2025).